Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

NCT04309474 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04309474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04309474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2020
Completion date
December 23, 2024
Enrollment
121 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke